Company: BNBX
Filing Date: 2025-12-22
Form Type: 10-K
Source: 0001104659-25-123342
Chunk: 26

Company: BNB PLUS CORP.
Filing Date: 2025-12-22
Form: 10-K
Item: Item 5
Chunk 26
---
 biopharmaceutical and diagnostics markets. Our nucleic acid production solutions enable cell-free manufacturing of DNA and RNA, which are essential components for a new generation of advanced biotherapeutics, such as gene therapies, adoptive cell therapies, messenger RNA therapeutics and DNA vaccines, as well as diagnostic applications.

On February 13, 2025, we announced our exit from our business operations relating to the manufacture and detection of DNA for industrial supply chains and security services (“DNA Tagging and Security Products and Services”) segment and completion of a workforce reduction of approximately 20% of our total headcount as of such date related primarily to employees within such segment.